Key takeaways for Hawaii
- • Wegovy (semaglutide) is FDA-approved for MASH with F2–F3 fibrosis (Aug 2025) — the first GLP-1 approved for a liver disease.
- • The approval was based on the phase 3 ESSENCE trial (MASH resolution + fibrosis improvement endpoints met).
- • Resmetirom (Rezdiffra) was the first MASH-specific drug (2024); Wegovy followed in 2025. Tirzepatide is promising but not yet MASH-approved.
- • Med-QUEST coverage rules apply for NAFLD / MASLD (Fatty Liver Disease) patients in Hawaii — see Medicaid section below.
- • 13 GLP-1 telehealth providers available nationwide.
Why GLP-1 medications for NAFLD / MASLD (Fatty Liver Disease)
Wegovy (semaglutide 2.4 mg) was FDA-approved in August 2025 for MASH with moderate-to-advanced (F2–F3) liver fibrosis — the first GLP-1 approved for a liver disease — based on the phase 3 ESSENCE trial (MASH resolution and fibrosis-improvement endpoints met). Resmetirom (Rezdiffra) was the first MASH-specific drug (approved 2024). Tirzepatide showed similar liver-fat and fibrosis improvements in SYNERGY-NASH but is not yet FDA-approved for MASH. Evidence grade: A (phase 3 RCT for semaglutide). Outside the Wegovy MASH indication, GLP-1s are used off-label or based on coexisting obesity/T2D indications.
Hawaii-specific context
Hawaii has telehealth access concentrated in Honolulu, East Honolulu, Pearl City metros, with additional reach to Hilo and Kailua. Queen's Health Systems, Hawaii Pacific Health is the largest in-state academic medical center for endocrine + obesity-medicine specialty consults. The state health authority publishes prescribing + coverage updates at health.hawaii.gov.
Hawaiitelehealth & pricing rules
- • Hawaii requires a live video consultation before a GLP-1 prescription.